Literature DB >> 30690070

Nanobodies: New avenues for imaging, stabilizing and modulating GPCRs.

Timo W M De Groof1, Vladimir Bobkov2, Raimond Heukers3, Martine J Smit4.   

Abstract

The family of G protein-coupled receptors (GPCRs) is the largest class of membrane proteins and an important drug target due to their role in many (patho)physiological processes. Besides small molecules, GPCRs can be targeted by biologicals including antibodies and antibody fragments. This review describes the use of antibodies and in particular antibody fragments from camelid-derived heavy chain-only antibodies (nanobodies/VHHs/sdAbs) for detecting, stabilizing, modulating and therapeutically targeting GPCRs. Altogether, it becomes increasingly clear that the small size, structure and protruding antigen-binding loops of nanobodies are favorable features for the development of selective and potent GPCRs-binding molecules. This makes them attractive tools to modulate GPCR activity but also as targeting modalities for GPCR-directed therapeutics. In addition, these antibody-fragments are important tools in the stabilization of particular conformations of these receptors. Lastly, nanobodies, in contrast to conventional antibodies, can also easily be expressed intracellularly which render nanobodies important tools for studying GPCR function. Hence, GPCR-targeting nanobodies are ideal modalities to image, stabilize and modulate GPCR function.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Antibodies; Crystallization; G protein-coupled receptors; Imaging; Modulation; Nanobodies

Mesh:

Substances:

Year:  2019        PMID: 30690070     DOI: 10.1016/j.mce.2019.01.021

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  15 in total

Review 1.  G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.

Authors:  Stacy Gelhaus Wendell; Hao Fan; Cheng Zhang
Journal:  Pharmacol Rev       Date:  2020-01       Impact factor: 25.468

Review 2.  Exploring cellular biochemistry with nanobodies.

Authors:  Ross W Cheloha; Thibault J Harmand; Charlotte Wijne; Thomas U Schwartz; Hidde L Ploegh
Journal:  J Biol Chem       Date:  2020-08-31       Impact factor: 5.157

3.  Structure and development of single domain antibodies as modules for therapeutics and diagnostics.

Authors:  Robert J Hoey; Hyeyoung Eom; James R Horn
Journal:  Exp Biol Med (Maywood)       Date:  2019-10-09

4.  In Vitro Assessment of Binding Affinity, Selectivity, Uptake, Intracellular Degradation, and Toxicity of Nanobody-Photosensitizer Conjugates.

Authors:  Irati Beltrán Hernández; Timo W M De Groof; Raimond Heukers; Sabrina Oliveira
Journal:  Methods Mol Biol       Date:  2022

Review 5.  Finding the Perfect Fit: Conformational Biosensors to Determine the Efficacy of GPCR Ligands.

Authors:  Keith M Olson; Andra Campbell; Andrew Alt; John R Traynor
Journal:  ACS Pharmacol Transl Sci       Date:  2022-08-14

6.  Nanobody-Targeted Photodynamic Therapy Selectively Kills Viral GPCR-Expressing Glioblastoma Cells.

Authors:  Timo W M De Groof; Vida Mashayekhi; Tian Shu Fan; Nick D Bergkamp; Javier Sastre Toraño; Jeffrey R van Senten; Raimond Heukers; Martine J Smit; Sabrina Oliveira
Journal:  Mol Pharm       Date:  2019-06-19       Impact factor: 4.939

7.  Monitoring Allosteric Interactions with CXCR4 Using NanoBiT Conjugated Nanobodies.

Authors:  Mark Soave; Raimond Heukers; Barrie Kellam; Jeanette Woolard; Martine J Smit; Stephen J Briddon; Stephen J Hill
Journal:  Cell Chem Biol       Date:  2020-06-30       Impact factor: 8.116

Review 8.  Therapeutic Nanobodies Targeting Cell Plasma Membrane Transport Proteins: A High-Risk/High-Gain Endeavor.

Authors:  Raf Van Campenhout; Serge Muyldermans; Mathieu Vinken; Nick Devoogdt; Timo W M De Groof
Journal:  Biomolecules       Date:  2021-01-06

9.  Selective targeting of ligand-dependent and -independent signaling by GPCR conformation-specific anti-US28 intrabodies.

Authors:  Timo W M De Groof; Nick D Bergkamp; Raimond Heukers; Truc Giap; Maarten P Bebelman; Richard Goeij-de Haas; Sander R Piersma; Connie R Jimenez; K Christopher Garcia; Hidde L Ploegh; Marco Siderius; Martine J Smit
Journal:  Nat Commun       Date:  2021-07-16       Impact factor: 17.694

10.  Targeting the latent human cytomegalovirus reservoir for T-cell-mediated killing with virus-specific nanobodies.

Authors:  Timo W M De Groof; Elizabeth G Elder; Eleanor Y Lim; Raimond Heukers; Nick D Bergkamp; Ian J Groves; Mark Wills; John H Sinclair; Martine J Smit
Journal:  Nat Commun       Date:  2021-07-21       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.